News & Blog
Latest from the Blog
-
September 30, 2019 September Superstars Shine Bright During Childhood Cancer Awareness Month
Thank you for joining us throughout the month of September to honor and support children and families that have been affected by pediatric brain tumors, the leading cause of cancer-related death in children, as well as the most commonly diagnosed cancer in children 14 years old and younger. It’s clear the brain tumor community has […]
Read more | -
September 24, 2019 Defeat Pediatric Brain Tumors Research Collaborative: 2018 Progress Update and 2019 Work in Progress
The Defeat Pediatric Brain Tumors Research Collaborative has brought together some of the world’s best pediatric brain tumor research teams from St. Jude Children’s Research Hospital, Montreal Children’s Hospital/McGill University Health Centre, and the German Cancer Research Center to work in a team environment and share data and other resources to speed the scientific discovery […]
Read more | -
September 16, 2019 Can Newly Approved “Tissue Agnostic” Drugs Benefit Pediatric High-grade Glioma Patients?
Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval* to the drug Rozlytrek (entrectinib, Genentech/Roche**) as a treatment for patients, 12 years or older, whose tumors have a specific genetic defect known as an “NTRK gene fusion.”*** This is now the second drug that the FDA has approved to treat patients with this […]
Read more |